Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

Acta Pharmacologica Sinica

Volumn 31, Issue 5, 2010, Pages 647-648

  Sun, Yi Hua ^a,b   Fang, Rong ^a   Gao, Bin ^a   Han, Xiang Kun ^a   Zhang, Jun Hua ^b   Pao, William ^c   Chen, Hai Quan ^b   Ji, Hong Bin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE;

CHINESE; COMPARATIVE STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; LETTER; LUNG ADENOCARCINOMA; MALE; PROTEIN DOMAIN; SEX DIFFERENCE; SMOKING; TUMOR DIFFERENTIATION; WILD TYPE;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 77952076471     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.43     Document Type: Letter

References (11)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
4. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008;60 Suppl 2: S23-S30.
5. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007;57:233-44.
6. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba, II, Fong KM, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. (Pubitemid 40425952)
7. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
8. Li Q, Zhao YL, Hao HJ, Li XH. EGFR gene mutation status among lung cancer patients in China. Zhonghua Zhong Liu Za Zhi 2007;29:270-3.
9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
10. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126:651-5.
11. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94.